SCHEMBL31412935

SCHEMBL31412935

COc1cc2nccc(Oc3ccc(NC(=O)C4(NC(=O)OC(C)(C)C)CC4)cc3F)c2cc1OC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 9/20 0.68
AXL P30530 4/20 0.68
KDR P35968 3/20 0.68
FLT3 P36888 10/20 0.62
MERTK Q12866 2/20 0.59
PDGFRA P16234 2/20 0.57
HDAC2 Q92769 2/20 0.57
HDAC8 Q9BY41 2/20 0.57
HDAC6 Q9UBN7 2/20 0.57
RET P07949 2/20 0.57
PDGFRB P09619 2/20 0.57
KIT P10721 2/20 0.57
HDAC10 Q969S8 1/20 0.55
HDAC11 Q96DB2 1/20 0.55
PLK4 O00444 1/20 0.55
STK25 O00506 1/20 0.55
CIT O14578 1/20 0.55
AURKA O14965 1/20 0.55
CHUK O15111 1/20 0.55
MUSK O15146 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31412934 0.92 MET (0.58) METAXLKDRFLT3MERTK
SCHEMBL31412928 0.85 MET (0.75) METAXLKDRFLT3MERTK
SCHEMBL31412939 0.82 MET (0.77) METAXLKDRFLT3MERTK
SCHEMBL31412941 0.82 MET (0.75) METAXLKDRFLT3MERTK
SCHEMBL373942 0.82 FGFR2 (0.59) METAXLKDRFLT3PDGFRA
SCHEMBL24414026 0.81 MET (0.89) METAXLKDRFLT3MERTK
Exelixis SCHEMBL371899 0.81 MET (1.00) METAXLKDRFLT3MERTK
Exelixis SCHEMBL29693473 0.81 MET (1.00) METAXLKDRFLT3MERTK
SCHEMBL374110 0.81 AXL (0.65) METAXLKDRFLT3PDGFRA
SCHEMBL14821079 0.81 MET (0.75) METAXLKDRFLT3MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4552695-A2 TYROSINE KINASES INHIBITORS AND USES THEREOF Great Novel Therapeutics Biotech & Medicals Corporation (TW) 2025-05-14 EP disclosed
US-20250120967-A1 TYROSINE KINASES INHIBITORS AND USES THEREOF Great Novel Therapeutics Biotech & Medicals Corporation (TW) 2025-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250120967-A1 TYROSINE KINASES INHIBITORS AND USES THEREOF LCK, LTK, HIF1AN MET 592/4885AXL 339/4885KDR 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.